Article Sidebar

PDF
Date Published: 08/07/2022
Online Published: 08/07/2022
Abstract Views: 152
Views PDF: 29
DOI: https://doi.org/10.55046/vjrnm.01.65.2021
Issue
No. 01 (2021)
Section
Scientific research
How to Cite
Nguyen Thi Kim , D., Mai Hong , S., Nguyen Khac , T., Le Ngoc, . H., Pham Dang , T., Pham Dang Tung, & Nguyen Quoc , T. (2022). Evaluation of 18fluorinfluorothymidine uptake in breast and lung-tumor bearing mice. Vietnamese Journal of Radiology and Nuclear Medicine, 01, 24 -29. https://doi.org/10.55046/vjrnm.01.65.2021

Evaluation of 18fluorinfluorothymidine uptake in breast and lung-tumor bearing mice

Nguyen Thi Kim Dung1,, Mai Hong Son1, Nguyen Khac That1, Le Ngoc Ha1, Pham Dang Tung1, Pham Dang Tung2, Nguyen Quoc Thang2
1 Nuclear Medicine Department, 108 Military Central Hospital, Hanoi 10000, Vietnam
2 Nuclear Medicine Unit, Vinmec Healthcare System, Hanoi 10000, Vietnam

Main Article Content

Abstract

Background: PET (positron emission tomography) techniques and radiopharmaceutical tracers are becoming increasingly common in clinical practice. Since 1991, 3’-deoxy-3’-18Fluorine-Fluorothymidine (18F-FLT) has been studied as a PET tracer for tumor proliferation assessment. The purpose of this study was to assess tracer uptake (%ID/g) in tumor-bearing mice and the relationship between uptake values and Ki-67 expression.
Materials and methods: two cell lines including breast cancer cell line 4T1 and lung cancer cell line LLC were inoculated into BALB/c mice. The radiotracer was then injected, and tumor resection was performed 20, 40, 60, and 90 minutes later. Gamma-ray spectrometer was used to calculate uptake values.
Results: The data show that the tumor’s %ID/g were 5.52 ± 0.23 and 4.66 ± 0.49 for the 4T1 and LLC tumors, respectively, at 90 minutes after injection. The LLC tumors presented a higher Ki-67 index than the 4T1 tumors (90.16 ± 2.93% vs 71.83 ± 3.54%).
Conclusion: In our model experiment, accumulation of the tracer in the tumor samples correlates with its malignancy which indicates that 18F-FLT could be a feasible PET tracer.

Article Details

References

1. Pauwels, E.K., et al., Positron-emission tomography with [18F]fluorodeoxyglucose. Part I. Biochemical uptake mechanism and its implication for clinical studies. J Cancer Res Clin Oncol, 2000. 126 (10): p. 549-59.
2. Mamede, M., et al., [18F]FDG uptake and PCNA, Glut-1, and Hexokinase-II expressions in cancers and inflammatory lesions of the lung. Neoplasia, 2005. 7 (4): p. 369-79.
3. Corrigan, A.J., P.J. Schleyer, and G.J. Cook, Pitfalls and Artifacts in the Use of PET/CT in Oncology Imaging. Semin Nucl Med, 2015. 45 (6): p. 481-99.
4. Jadvar, H., Molecular imaging of prostate cancer: PET radiotracers. AJR Am J Roentgenol, 2012. 199 (2): p. 278-91.
5. Couturier, O., et al., [Is 3’-deoxy-3’- [18F] fluorothymidine ([18F]-FLT) the next tracer for routine clinical PET after R [18F]-FDG?]. Bull Cancer, 2005. 92 (9): p. 789-98.
6. Schwartz, J.L., et al., Monitoring tumor cell proliferation by targeting DNA synthetic processes with thymidine and thymidine analogs. J Nucl Med, 2003. 44 (12): p. 2027-32.
7. Chalkidou, A., et al., Correlation between Ki-67 immunohistochemistry and 18F-fluorothymidine uptake in patients with cancer: A systematic review and meta-analysis. Eur J Cancer, 2012. 48 (18): p. 3499-513.
8. Shen, G., et al., Correlations of 18F-FDG and 18F-FLT uptake on PET with Ki-67 expression in patients with lung cancer: a meta-analysis. Acta Radiol, 2018. 59(2): p. 188-195.
9. Tao, K. et al., Imagable 4T1 model for the study of late stage breast cancer. BMC Cancer, 2008. 8: p. 228-228
10. Do, T.T. et al., Improved Anticancer Activity of the Malloapelta B-Nanoliposomal Complex against Lung Carcinoma. Appl. Sci. 2020, 10: p. 8148.
11. Shields, A.F., et al., Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med, 1998. 4 (11): p. 1334-6.
12. McKinley, E.T., et al., Limits of [18F]-FLT PET as a biomarker of proliferation in oncology. PLoS One, 2013. 8 (3): p. e58938.
13. Fueger, B.J., et al., Impact of animal handling on the results of 18F-FDG PET studies in mice. J Nucl Med, 2006. 47 (6): p. 999-1006.
14. Apisarnthanarax, S., et al., Early detection of chemoradioresponse in esophageal carcinoma by 3’-deoxy-3’-3H-fluorothymidine using preclinical tumor models. Clin Cancer Res, 2006. 12 (15): p. 4590-7.
15. Bao, X., et al., Early monitoring antiangiogenesis treatment response of Sunitinib in U87MG Tumor Xenograft by (18)F-FLT MicroPET/CT imaging. Biomed Res Int, 2014. 2014: p. 218578.
16. Everitt S.J., et al., Differential (18)F-FDG and (18)F-FLT Uptake on Serial PET/CT Imaging Before and During Definitive Chemoradiation for Non-Small Cell Lung Cancer. J Nucl Med. 2014. 55 (7): p. 1069-74.
17. Alwadani B., et al., Clinical value of 3’-deoxy-3’-[18F]fluorothymidine-positron emission tomography for diagnosis, staging and assessing therapy response in lung cancer. Insights Imaging. 2021. 12 (1): p. 90.
18. Woolf D.K., et al., Evaluation of FLT-PET-CT as an imaging biomarker of proliferation in primary breast cancer. Br J Cancer. 2014. 110 (12): p. 2847-54.